



CONDENSED INTERIM FINANCIAL
STATEMENTS FOR THE PERIOD
ENDED MARCH 31, 2026.



49 KM LAHORE MULTAN ROAD PAKISTAN

www.liven-pharma.com info@liven-pharma.com

+92-3-111-0-LIVEN

Table of contents

COMPANY'S INFORMATION.....	3
VISION AND MISSION STATEMENT	4
PROFILE OF DIRECTORS.....	5
DIRECTOR REPORT	7
ڈائریکٹرز کی رپورٹ.....	11
CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2026.	15

COMPANY'S INFORMATION

Board of Directors

Mr. Atif Hussain
Chairman

Mr. Kaashif Hussain
Chief Executive Officer

Ms. Firdous Shakir
Executive Director

Mr. Umar Mujib Shami
Non-Executive Director

Mr. Usman Mujib Shami
Non-Executive Director

Mr. Ahmad Shoaib Hashmi
Independent Director

Mr. Syed Raza Abbas
Independent Director

Audit Committee

Mr. Ahmad Shoaib Hashmi

Mr. Atif Hussain Siddiqi

Ms. Usman Mujib Shami

Human Resource & Remuneration Committee

Mr. Ahmad Shoaib Hashmi

Mr. Atif Hussain Siddiqi

Ms. Firdous Shakir

Chief Financial Officer

Mr. Muhammad Shah

Company Secretary

Mr. Muhammad Saeed

External Auditors

Reanda Haroon Zakaria Aamir Salman
Rizwan & Co Chartered Accountants

Legal Advisor

Saeed Associates

Share Registrar

F.D Registrar Services (pvt) Ltd

Bankers

Bank Al Habib Limited

Meezan Bank Limited
United Bank Limited

Registered Office

49-Km Lahore Multan Road Pakistan

+92-3-111-0-45836

info@liven-pharma.com

www.liven-pharma.com

VISION AND MISSION STATEMENT

Our Vision

Our business focus made explicit in this plan, renews our vision and strategic thinking on adding value to our target market segments. From average buyer to high-end institutions we will position ourselves in a manner to differentiate us from box pushers to serious minded totally committed purveyors of safe and reliable products.

Our marketing challenge is to position our product as the high-quality, high value-added yet affordable alternative to existing brands and similar products.

Our challenge is to strengthen our brand by giving the most effective and accurate product, rather than incentive based sales and marketing strategy.

From the import of the basic raw material to the procurement of excipients and packaging material our focus is to target the most reputed and prestigious manufacturers with concerned certifications as our vendors, so that what we produce for our customers is the compilation of the best what is available in the market.

We have long term targets and have set high goals for our short term results, that is why we believe in quality rather than quantity, perfection is our passion and so is the least required quality of our sector i.e. pharmaceutical manufacturing, but we take it seriously rather religiously we believe we have not chosen a business but a duty that is to endeavor ourselves in the service of humanity

Our Mission

Liven is a promise, a hope a life, a driving force more than just a pharmaceuticals manufacturing company endeavored in the business of cure, remedy and quality of life, our mission is to create a better world through our Business activities as well as our CSR activities. LIVEN is a name of a lively healthy and happy life. Welcome to the world of Liven Pharmaceuticals Ltd; where everybody is healthy wealthy and wise. LIVEN name means cause to be more lively, we creates to become more lively, rooted from a name itself we strive in providing healthcare, medicines, pharmaceuticals products and solutions to deprived, distressed and ailed to come to life and lively hood, leading by innovation to meet patient needs, and being a trusted partner for the healthcare community worldwide.

PROFILE OF DIRECTORS

MR. ATIF SIDDIQI - CHAIRMAN OF BOARD OF DIRECTORS

Mr. Atif, an accomplished industrialist, embarked on his professional career in 1999 with the establishment of his first venture, a manufacturing company specializing in empty glass ampoules for the pharmaceutical packaging industry. A graduate in BBA (Bachelors of Business Administration) from Premier College Lahore, he combines strong business acumen with extensive entrepreneurial experience.

Over the course of his career, he has successfully led multiple ventures, including Merchant's Glass, MG Construction, and Textile Temple, each of which has benefited from his strategic vision and hands-on leadership. His deep understanding of manufacturing operations, coupled with his commitment to operational excellence, has been a cornerstone of his professional success. Known for his industrious and perfectionist approach, Mr. Atif has consistently demonstrated the ability to deliver sustainable growth, innovation, and value creation throughout his career.

MR. KAASHIF HUSSAIN SIDDIQIE – CHIEF EXECUTIVE OFFICER & EXECUTIVE DIRECTOR

Mr. Kaashif Hussain is a visionary leader and entrepreneur with a strong academic background in Business Administration and Software Engineering, specializing in System Analysis and Design. He holds postgraduate degrees including an MBA and an MSc in Information Technology from Al-Khair University, Lahore.

He began his entrepreneurial journey in 1998 by establishing Heavenly Impex, an import business supplying glass packaging materials to pharmaceutical manufacturers in Pakistan. In 1999, he expanded the venture by founding Merchant's Glass, a manufacturing company. Over the years, Mr. Kaashif has also been associated with other successful ventures, including MG Constructions and Textile Temple.

Known for his analytical approach, decisiveness, and optimism, Mr. Kaashif has consistently demonstrated the qualities of a true leader, driving organizations toward growth and success.

MR. UMER MUJIB SHAMI – NON-EXECUTIVE DIRECTOR

Mr. Umer Shami is an accomplished business leader with extensive experience in the oil, real estate, and media sectors. He holds an MBA from the Lahore University of Management Sciences (LUMS) and currently serves as a Director at New Life Developers Ltd., where he oversees real estate projects in Lahore and Gwadar. Under his leadership, Euro Oil has emerged as a growing brand in Pakistan's oil and gas industry. Prior to this role, he served as Chief Executive of Fuel Tech Ltd. A leading fuel distribution company catering to major national and multinational clients. Mr. Umer is widely recognized for his strategic vision and his ability to transform innovative ideas into successful business ventures.

MR. USMAN MUJIB SHAMI – NON-EXECUTIVE DIRECTOR

Mr. Umer Mujib Shami holds a Bachelor's degree from the Institute of Business Administration (IBA), Karachi, one of Pakistan's leading business schools. He further pursued a Master's degree in International Business from Hult International Business School, Shanghai.

In addition to serving as a Board Member of Euro Oil, Mr. Usman manages Pakistan's largest digital media house and acts as a marketing consultant for a premier housing development project in the emerging port city of Gwadar.

Mr. Usman is recognized for his analytical acumen, lean management practices, and dynamic leadership in business development, which distinguish him among top industry executives.

MR. AHMAD SHOAIB HASHMI – INDEPENDENT DIRECTOR

Mr. Ahmad Shoaib Hashmi is a distinguished businessman with extensive experience in the pharmaceutical industry. As a founding member of Mass Pharma, he has served for over 28 years in key leadership roles, including Director of Procurement and Director of International Business. With more than 35 years of professional expertise, his career encompasses pharmaceutical manufacturing, distribution, imports, and international trade.

Mr. Ahmed Shoaib is widely recognized for his strategic leadership and in-depth industry knowledge, having played a pivotal role in driving growth, developing global partnerships, and contributing to the advancement of the pharmaceutical sector. He is also among the pioneers who introduced innovative healthcare technologies in Pakistan, such as Enhanced External Counter pulsation (EECP) treatment for cardiac patients who are unable to undergo invasive procedures.

Ms. FIRDOUS SHAKIR – EXECUTIVE DIRECTOR

Ms. Shakir is a highly experienced professional with over 48 years of expertise in managing human resources and successfully operating small and medium enterprises. She has independently managed a dairy and protein farm, demonstrating strong leadership, organizational management, and operational skills.

Throughout her career, she has developed extensive knowledge in workforce management, supply chain oversight, and sustainable business practices, enabling her to build and maintain efficient business operations. Her ability to adapt to evolving market dynamics and her proven track record in entrepreneurship reflect her strategic mindset and commitment to long-term growth.

MR. SYED RAZA ABBAS JAFFERY – INDEPENDENT DIRECTOR

Mr. Syed Raza Abbas serves on the Board of the Company as a representative of National Investment Trust Limited (NITL), Pakistan's largest and oldest asset management company. He has been associated with NITL since 2001 and currently holds the position of Head of Equities, where he leads the equity investment team and oversees portfolio management across multiple funds. His responsibilities include developing investment strategies, conducting in-depth market research, and ensuring optimal asset allocation to maximize returns for investors.

Prior to joining NITL, Mr. Raza served as Manager Treasury at Doha Bank Limited (Pakistan), where he gained valuable experience in treasury operations, liquidity management, and financial risk mitigation.

Mr. Raza holds an MBA in Banking & Finance and also represents NITL on the boards of several other listed companies. Through his governance roles, he actively contributes to promoting transparency, accountability, and sustainable growth within these organizations.

DIRECTOR REPORT

We are pleased to present the condensed interim financial statements for the period ended March 31, 2026.

Composition of Board

1.	Male	6
2.	Female	1
Sr. No.	Category	Name
1	Independent Director	1. Mr. Ahmad Shoaib Hashmi 2. Mr. Syed Raza Abbass
2	Non-Executive Director	1. Mr. Atif Hussain 2. Mr. Umar Mujib Shami 3. Mr. Usman Mujib Shami
3	Executive Director	1. Mr. Kaashif Hussain 2. Ms. Firdous Shakir (Female director)

PRINCIPAL ACTIVITIES

The principal activity of the company is manufacturing and sale of pharmaceutical products.

OVERVIEW OF ECONOMY AND BUSINESS

Macroeconomic Overview

During the quarter ended March 31, 2026, Pakistan's macroeconomic environment remained relatively stable. Inflationary pressures and exchange rate volatility continued to influence input costs; however, no significant economic developments occurred that materially impacted the Company's overall performance during the period.

Sector Performance

The pharmaceutical sector continued to exhibit resilience, driven by consistent demand for essential healthcare products. Regulatory engagement and sustained healthcare requirements remained key supporting factors for the sector.

Industry Challenges

The sector continued to face challenges related to regulatory pricing constraints and reliance on imported raw materials, exposing manufacturers to currency fluctuations and supply chain risks.

The Company continued to address these challenges through prudent operational and financial management.

FINANCIAL HIGHLIGHTS

During the three-month period ended March 31, 2026, the Company recorded revenue of Rs. 29.247 million compared to Rs. 14.755 million in the corresponding period last year.

Gross profit for the period stood at Rs. 8.422 million (March 31, 2025: Rs. 3.739 million).

Administrative and operating expenses remained significant during the period, resulting in an operating loss of Rs. 5.531 million (March 31, 2025: Rs. 7.308 million).

After accounting for other income, finance costs, and taxation, the loss after tax for the period was Rs. 3.956 million, compared to a loss of Rs. 9.621 million in the corresponding period last year.

The Board remains focused on improving operational efficiency and controlling costs while enhancing revenue streams.

RELATED PARTY TRANSACTIONS

The Company ensures compliance with Code of Corporate Governance for all the related party transactions. The details of these transactions are provided in note no. 22 of the annexed financial statements.

EARNING PER SHARE

The loss per share (basic and diluted) for the three-month period ended March 31, 2026 was Rs. 0.03, as compared to loss per share of Rs. 0.10 in the corresponding period last year.

COMMITTEES OF THE BOARD

Audit committee

Audit committee comprises of three members from the Board. The chairman of the Board is an independent director as required in the CCG Regulations 2019 while the remaining two are non-executive directors. The Board of Directors has set out terms of reference for the audit committee. The audit committee reviews the annual and quarterly financial statements and holds its meeting prior to the Board meetings. The following are the members of the audit committee.

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Mr. Usman Mujib Shami	Member (Non-Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

Meeting And Attendance

Board Audit Committee: One (1) meeting of the Audit Committee was held during the period.

Human Resource & Remuneration Committee

The committee consists of three members from the Board; one is independent director, one is non-executive director and the one is executive director. The Chairman of the committee is the independent non-executive director. The committee reviews and formulates the HR & management policies of the company. The Committee is also responsible for the remuneration of employees and ensures that it is aligned with the Company's business strategy and long-term interests. The following are the members of the Human Resource committee.

Sr. No.	Name	Designation
i.	Mr. Ahmad Shoaib Hashmi	Chairman (Independent Director)
ii.	Mr. Atif Hussain Siddiqi	Member (Non-Executive Director)
iii.	Ms. Firdous Shakir	Member (Executive Director)
iv.	Mr. Muhammad Saeed	Secretary

Auditors

The external auditors of the Company, Reanda Haroon Zakaria Aamir Salman Rizwan & Co., Chartered Accountants, were re-appointed at the Annual General Meeting held on November 26, 2025, to hold office until the conclusion of the next Annual General Meeting, at a remuneration fixed by the Board of Directors.

DIVERSITY, EQUITY AND INCLUSION

The Company remains committed to promoting diversity, equity, and inclusion across its operations, ensuring equal opportunity and a respectful workplace environment.

ENVIRONMENT, HEALTH AND SAFETY

The Company continues to prioritize workplace safety and compliance with applicable health and safety standards, ensuring a safe working environment across all operations.

CORPORATE SOCIAL RESPONSIBILITY

The Company continues its CSR initiatives focusing on healthcare awareness and community support aligned with its operational footprint.

ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Company maintains an adequate system of internal financial controls to ensure reliable financial reporting, safeguarding of assets, and compliance with laws and regulations. These controls are regularly reviewed by management and the Audit Committee.

STATE OF COMPANY'S AFFAIRS AND CORPORATE AND FINANCIAL REPORTING FRAMEWORK

The condensed interim financial statements fairly present the Company's financial position, results of operations, and cash flows.

Accounting policies have been consistently applied, and estimates are based on reasonable judgment. Proper books of account have been maintained in accordance with applicable International Accounting Standards as adopted in Pakistan.

There is no material uncertainty regarding the Company's ability to continue as a going concern.

MATERIAL CHANGES

During the period under review, the Company received confirmation from the Central Depository Company (CDC) regarding the credit of right shares.

As per CDC communication dated January 05, 2026, the right securities of the Company were credited into respective accounts in the Central Depository System.

Consequently, the paid-up share capital of the Company increased to 113,040,367 ordinary shares.

SUBSEQUENT EVENTS

There were no material events subsequent to the period end that require disclosure or adjustment in these condensed interim financial statements.

DIVIDENDS

No dividend has been declared during the period under review.

RISK MANAGEMENT AND RISK ASSESSMENT

The Board continues to oversee the Company's risk management framework. Key operational, financial, and regulatory risks are regularly assessed, and appropriate mitigation strategies are implemented.

FUTURE CHALLENGES & PROSPECTS

The Board remains cautiously optimistic. Management is focused on cost optimization, operational efficiency, and sustainable growth while navigating industry challenges.

ACKNOWLEDGMENT

The Directors express their appreciation to the shareholders, employees, customers, and business partners for their continued support and confidence. During the period under review, the Company continued its commitment towards corporate social responsibility initiatives. These efforts primarily focus on community welfare, healthcare awareness, and support initiatives in areas surrounding the Company's operational facilities, in line with its CSR objectives.

For and on behalf of the Board

Kaashif Hussain Siddique
Chief Executive Officer



Atif Hussain Siddique
Director


Dated: 29-April-2026

ڈائریکٹرز کی رپورٹ

ہمیں یہ پیش کرتے ہوئے خوشی ہو رہی ہے کہ ہم 31 مارچ 2026 کو ختم ہونے والی مدت کے لیے مختصر عبوری مالی بیانات پیش کر رہے ہیں۔

بورڈ کی تشکیل

مرد: 6
خواتین: 1

نمبر شمار	زمرہ	نام
1	آزاد ڈائریکٹر	مسٹر احمد شعیب ہاشمی مسٹر سید رضا عباس
2	نان ایگزیکٹو ڈائریکٹر	مسٹر عاطف حسین مسٹر عمر مجیب شامی مسٹر عثمان مجیب شامی
3	ایگزیکٹو ڈائریکٹر	مسٹر کاشف حسین مس فردوس شاکر (خاتون ڈائریکٹر)

اہم سرگرمیاں

کمپنی کی بنیادی سرگرمی دواسازی مصنوعات کی تیاری اور فروخت ہے۔

معاشی و کاروباری جائزہ

معاشی جائزہ

31 مارچ 2026 کو ختم ہونے والی سہ ماہی کے دوران پاکستان کا معاشی ماحول مجموعی طور پر مستحکم رہا۔ مہنگائی کے دباؤ اور شرح تبادلہ میں اتار چڑھاؤ نے لاگت کو متاثر کیا، تاہم کوئی ایسی بڑی معاشی تبدیلی رونما نہیں ہوئی جس کا کمپنی کی کارکردگی پر نمایاں اثر پڑا ہو۔

سیکٹر کی کارکردگی

فارماسیوٹیکل سیکٹر نے اپنی مضبوطی برقرار رکھی، جس کی بنیادی وجہ ضروری طبی مصنوعات کی مسلسل طلب ہے۔ صحت کے شعبے کی ضروریات اور ریگولیٹری معاملات اس سیکٹر کے استحکام میں اہم کردار ادا کرتے رہے۔

صنعتی چیلنجز

اس شعبے کو بدستور قیمتوں کے ریگولیٹری کنٹرول اور درآمدی خام مال پر انحصار جیسے مسائل کا سامنا رہا، جس کے باعث زر مبادلہ میں اتار چڑھاؤ اور سپلائی چین کے خطرات موجود رہے۔ کمپنی نے ان چیلنجز کا مقابلہ محتاط حکمت عملی کے ذریعے کیا۔

مالی نمایاں پہلو

31 مارچ 2026 کو ختم ہونے والی سہ ماہی کے دوران کمپنی کی آمدن 29.247 ملین روپے رہی جبکہ گزشتہ سال اسی مدت میں یہ 14.755 ملین روپے تھی۔ مجموعی منافع 8.422 ملین روپے رہا (31 مارچ 2025: 3.739 ملین روپے)۔

انتظامی اور دیگر اخراجات زیادہ رہنے کے باعث آپریٹنگ نقصان 5.531 ملین روپے رہا (31 مارچ 2025: 7.308 ملین روپے)۔
 دیگر آمدن، مالی اخراجات اور ٹیکس کے بعد خالص نقصان 3.956 ملین روپے رہا جبکہ گزشتہ سال اسی مدت میں نقصان 9.621 ملین روپے تھا۔
 بورڈ اخراجات پر کنٹرول اور آپریشنل بہتری پر توجہ مرکوز کیے ہوئے ہے۔

متعلقہ فریقین کے ساتھ لین دین

کمپنی متعلقہ فریقین کے ساتھ تمام لین دین کارپوریٹ گورننس کے ضابطوں کے مطابق انجام دیتی ہے۔ ان لین دین کی تفصیل مالی بیانات کے نوٹ نمبر 22 میں دی گئی ہے۔

فی حصص آمدنی

31 مارچ 2026 کو ختم ہونے والی سہ ماہی کے لیے فی حصص نقصان (بنیادی اور تخفیف شدہ) 0.03 روپے رہا جبکہ گزشتہ سال اسی مدت میں یہ 0.10 روپے تھا۔

بورڈ کی کمیٹیاں

آڈٹ کمیٹی

آڈٹ کمیٹی بورڈ کے تین اراکین پر مشتمل ہے۔ اس کے چیئرمین ایک آزاد ڈائریکٹر ہیں جبکہ دیگر اراکین نان ایگزیکٹو ڈائریکٹرز ہیں۔ کمیٹی مالی بیانات کا جائزہ لیتی ہے اور بورڈ اجلاس سے قبل اپنی میٹنگ منعقد کرتی ہے۔

نمبر شمار	نام	عہدہ
i	مسٹر احمد شعیب ہاشمی	چیئرمین (آزاد ڈائریکٹر)
ii	مسٹر عاطف حسین صدیقی	رکن (نان ایگزیکٹو ڈائریکٹر)
iii	مسٹر عثمان مجیب شامی	رکن (نان ایگزیکٹو ڈائریکٹر)
iv	مسٹر محمد سعید	سیکرٹری

مدت کے دوران آڈٹ کمیٹی کا ایک اجلاس منعقد ہوا۔

بیومن ریسورس و ریمونریشن کمیٹی

یہ کمیٹی ایک آزاد، ایک نان ایگزیکٹو اور ایک ایگزیکٹو ڈائریکٹر پر مشتمل ہے۔ کمیٹی کمپنی کی بیومن ریسورس پالیسیز اور معاوضہ ڈھانچے کا جائزہ لیتی ہے۔

نمبر شمار	نام	عہدہ
i	مسٹر احمد شعیب ہاشمی	چیئرمین (آزاد ڈائریکٹر)
ii	مسٹر عاطف حسین صدیقی	رکن (نان ایگزیکٹو ڈائریکٹر)
iii	مس فردوس شاکر	رکن (ایگزیکٹو ڈائریکٹر)
iv	مسٹر محمد سعید	سیکرٹری

آڈیٹرز

کمپنی کے بیرونی آڈیٹرز، ریانڈا ہارون زکریا عامر سلمان رضوان اینڈ کمپنی، چارٹرڈ اکاؤنٹنٹس، کو 26 نومبر 2025 کو منعقدہ سالانہ جنرل میٹنگ میں دوبارہ مقرر کیا گیا۔

تنوع، مساوات اور شمولیت

کمپنی اپنے تمام آپریشنز میں تنوع، مساوات اور شمولیت کو فروغ دینے کے لیے پُر عزم ہے اور تمام ملازمین کو مساوی مواقع فراہم کرتی ہے۔

ماحولیات، صحت اور تحفظ

کمپنی محفوظ اور صحت مند کام کے ماحول کو یقینی بنانے کے لیے تمام ضروری اقدامات کرتی ہے اور متعلقہ قوانین کی پابندی کرتی ہے۔

کارپوریٹ سماجی ذمہ داری

کمپنی اپنی کارپوریٹ سماجی ذمہ داری کے تحت کمیونٹی ویلفیئر، صحت سے متعلق آگاہی اور مقامی سطح پر فلاحی اقدامات جاری رکھے ہوئے ہے۔

اندرونی مالیاتی کنٹرولز کی کفایت

کمپنی کے پاس اندرونی مالیاتی کنٹرولز کا مؤثر نظام موجود ہے جو مالیاتی رپورٹنگ کی درستگی، اثاثوں کے تحفظ اور قوانین کی پابندی کو یقینی بناتا ہے۔

کمپنی کے معاملات اور مالیاتی رپورٹنگ فریم ورک

عبوری مالی بیانات کمپنی کی مالی حالت، کارکردگی اور کیش فلو کی درست عکاسی کرتے ہیں۔ اکاؤنٹنگ پالیسیز کو مستقل بنیادوں پر اپنایا گیا ہے اور اندازے محتاط اور معقول بنیادوں پر کیے گئے ہیں۔ کمپنی کے جاری رہنے کے بارے میں کوئی اہم غیر یقینی صورتحال موجود نہیں ہے۔

اہم تبدیلیاں

مدت کے دوران کمپنی کو سینٹرل ڈیپازٹری کمپنی (CDC) کی جانب سے رائٹ شیئرز کے کریڈٹ کی تصدیق موصول ہوئی۔ 05 جنوری 2026 کو جاری کردہ اطلاع کے مطابق کمپنی کے رائٹ شیئرز متعلقہ اکاؤنٹس میں منتقل کر دیے گئے۔ اس کے نتیجے میں کمپنی کا ادا شدہ سرمایہ بڑھ کر 113,040,367 حصص ہو گیا۔

بعد از تاریخ واقعات

مدت کے اختتام کے بعد کوئی اہم واقعہ پیش نہیں آیا جس کا ان مالی بیانات میں انکشاف ضروری ہو۔

منافع کی تقسیم

اس مدت کے دوران کوئی منافع (ڈیویڈنڈ) اعلان نہیں کیا گیا۔

رسک مینجمنٹ اور جائزہ

بورڈ کمپنی کے رسک مینجمنٹ فریم ورک کی نگرانی جاری رکھے ہوئے ہے اور اہم خطرات کا باقاعدہ جائزہ لیا جاتا ہے۔

مستقبل کے امکانات

بورڈ کمپنی کے مستقبل کے بارے میں محتاط طور پر پُر امید ہے اور انتظامیہ لاگت میں کمی اور پائیدار ترقی پر توجہ دے رہی ہے۔

اظہارِ تشکر

ڈائریکٹرز کمپنی کے شیئر ہولڈرز، ملازمین، صارفین اور دیگر متعلقہ فریقین کے مسلسل اعتماد اور تعاون پر ان کا شکریہ ادا کرتے ہیں۔

بورڈ
L I V E N
Pharma Limited.
کاشفین صدیقی
چیف ایگزیکٹو آفیسر


L I V E N
Pharma Limited.
عالمہ مسعود صدیقی
ڈائریکٹر

بتاریخ: 29 اپریل، 2026


LIVEN PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT MARCH 31, 2026

	Note	Un-audited March 31, 2026 (Rupees)	Audited June 30, 2025 (Rupees)
ASSETS			
Non-current assets			
Property, plant and equipment	7	667,522,497	666,512,380
Intangible assets	8	8,775,309	8,440,679
Total non-current assets		676,297,806	674,953,059
Current assets			
Trade debts	9	3,978,611	9,402,578
Stock in trade	10	119,919,484	123,324,881
Tax refund due from government		291,314	-
Advances, deposits and prepayments	11	3,135,437	7,339,727
Cash and bank balances	12	178,796,670	7,884,396
Total current assets		306,121,516	147,951,582
TOTAL ASSETS		982,419,322	822,904,641
EQUITY AND LIABILITIES			
Share capital and reserves			
Share capital			
Issued, subscribed and paid-up share capital		1,130,403,670	930,403,670
Capital reserve			
Surplus on revaluation on property, plant and equipment		-	-
Revenue reserve			
Accumulated loss		(302,446,730)	(296,543,276)
TOTAL EQUITY		827,956,940	633,860,394
LIABILITIES			
Non-current liabilities			
Lease liabilities	13	752,930	1,247,868
Long term financing	14	3,209,962	5,098,065
Deferred taxation		69,690,351	92,272,765
Total non-current liabilities		73,653,243	98,618,698
Current liabilities			
Trade and other payables	15	57,295,655	61,720,121
Loan from related parties	16	14,047,263	14,047,263
Running finance		5,930,439	11,185,166
Mark up accrued		110,700	386,020
Current portion of long term liabilities	17	3,425,082	3,086,979
Provision for taxation		-	-
Total current liabilities		80,809,139	90,425,549
TOTAL LIABILITIES		154,462,382	189,044,247
TOTAL EQUITY AND LIABILITIES		982,419,322	822,904,641
CONTINGENCIES AND COMMITMENTS	18		

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive



Director




Chief Financial Officer




LIVEN PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS
FOR THE NINE MONTHS PERIOD AND THREE MONTHS PERIOD ENDED MARCH 31, 2026

	Note	NINE MONTHS ENDED		QUARTER ENDED	
		Un-audited Mar 31, 2026	Un-audited Mar 31, 2025	Un-audited Mar 31, 2026	Un-audited Mar 31, 2025
		(Rupees)	(Rupees)	(Rupees)	(Rupees)
Revenue		92,626,966	120,790,277	29,246,769	14,754,781
Cost of sales		(62,278,309)	(82,757,309)	(20,824,558)	(11,015,442)
Gross profit		30,348,657	38,032,968	8,422,211	3,739,339
Administrative and general expenses		(26,943,653)	(28,077,691)	(8,405,807)	(7,192,740)
Selling and distribution expenses		(9,395,690)	(6,608,495)	-	(3,843,125)
Other expenses		(30,072,740)	-	(5,296,314)	-
Finance costs		(1,557,019)	(14,434)	(252,012)	(11,284)
Operating (loss) / profit		(37,620,445)	3,332,345	(5,531,923)	(7,307,813)
Other income	19	10,369,338	119,295,890	380,969	-
(Loss) / profit before levies and taxation		(27,251,107)	122,628,235	(5,150,954)	(7,307,813)
Levies	20	(1,234,761)	-	(365,585)	-
(Loss) / profit before taxation		(28,485,868)	122,628,235	(5,516,538)	(7,307,813)
Taxation	21	22,582,414	(11,772,551)	1,560,813	(2,312,769)
Profit / (loss) after taxation		(5,903,454)	110,855,684	(3,955,725)	(9,620,582)
Earning / (loss) per share - basic and diluted		(0.06)	1.55	(0.03)	(0.10)


The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive



Director




Chief Financial Officer




LIVEN PHARMA LIMITED
**CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME
 FOR THE NINE MONTHS PERIOD AND THREE MONTHS PERIOD ENDED MARCH 31, 2026**

Note	NINE MONTHS ENDED		QUARTER ENDED	
	Un-audited March 31, 2026 (Rupees)	Un-audited March 31, 2025 (Rupees)	Un-audited March 31, 2026 (Rupees)	Un-audited March 31, 2025 (Rupees)
Profit / (loss) after taxation	(5,903,454)	110,855,684	(3,955,725)	(9,620,582)
Other comprehensive income				
Items that may be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified to profit or loss	-	-	-	-
Total other comprehensive income for the period	-	-	-	-
Total comprehensive income / (loss) for the period	(5,903,454)	110,855,684	(3,955,725)	(9,620,582)

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive



Director




Chief Financial Officer




LIVEN PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED MARCH 31, 2026

	Note	Un-audited March 31, 2026 (Rupees)	Un-audited March 31, 2025 (Rupees)
CASH FLOWS FROM OPERATING ACTIVITIES			
(Loss) / profit before taxation		(28,485,868)	122,628,235
Adjustments for non cash and other items:			
Depreciation on property, plant and equipment		18,689,754	18,316,276
Depreciation on right of use assets		933,368	-
Amortization on intangible assets		2,485,041	1,540,083
Impact of merger		-	(9,321,035)
Gain on disposal of fixed assets		(9,933,636)	(85,424,621)
Liability written off		-	(33,871,269)
Provision for obsolete stock		19,943,730	-
Allowance for expected credit loss		9,571,930	-
Finance cost		1,557,019	-
		<u>43,247,205</u>	<u>(108,760,566)</u>
Operating profit before working capital changes		14,761,337	13,867,669
Working capital changes			
Decrease / (increase) in current assets:			
Stock in trade		(16,538,333)	(138,820,765)
Trade debts		(4,147,963)	(132,054,547)
Advances, deposits and prepayments		4,204,290	(12,203,750)
(Decrease) / increase in current liabilities:			
Short term borrowings		(3,214,362)	22,005,016
Trade and other payables		(4,424,466)	17,109,667
Cash used in operations	A	(9,359,497)	(230,096,710)
Finance costs paid		(1,832,339)	-
Taxes paid		(291,314)	-
Net cash used in operating activities		(11,483,150)	(230,096,710)
CASH FLOWS FROM INVESTING ACTIVITIES			
Adjustment of loan against disposal of fixed assets		-	205,080,348
Proceeds from disposal of property, plant and equipment		12,560,100	-
Payment for acquisition of intangible asset		(2,819,670)	(56,000)
Payments for acquisition of property, plant and equipment		(23,259,703)	(13,931,500)
Net cash (used in) / generated from investing activities	B	(13,519,273)	191,092,848
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from issuance of shares		200,000,000	-
Payments against lease liabilities		(428,957)	-
Proceeds from running finance		50,921,419	-
Repayments against running finance		(52,961,784)	-
Loan received from related parties		-	226,343,114
Adjustment of loan against the disposal of fixed assets		-	(204,636,018)
Repayments against long term finance		(1,615,981)	-
Net cash generated in financing activities	C	195,914,697	21,707,096
Net increase / (decrease) in cash and cash equivalents	A+B+C	170,912,274	(17,296,766)
Cash and cash equivalents at the beginning of the period		7,884,396	38,000
Opening cashflows of amalgamated entity		-	17,352,049
Cash and cash equivalents at the end of the period		178,796,670	93,283



Chief Executive



Director




Chief Financial Officer




LIVEN PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE NINE MONTHS ENDED MARCH 31, 2026

Particulars	Share capital	Capital reserve	Revenue reserve	Total equity
	Issued, subscribed and paid-up share capital	Surplus on revaluation of property, plant and equipment	Accumulated (loss)/profit	
Rupees.....			
Balance as at July 1, 2024 (audited)	121,237,000	38,056,582	-293,089,484	(133,795,902)
Shares issued in accordance with scheme of merger	809,166,670	-	-	809,166,670
Impact of merger arrangement	-	-	109,680,240	109,680,240
Comprehensive income for the period				
Profit after taxation	-	-	110,855,684	110,855,684
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	-	-	110,855,684	110,855,684
Surplus relating to disposal net of deferred tax transferred to retained earnings	-	(38,056,582)	38,056,582	-
Balance as at March 31, 2025 (un-audited)	930,403,670	-	(34,496,978)	895,906,692
Balance as at July 1, 2025 (audited)	930,403,670	-	(296,543,276)	633,860,394
Transactions with Owners:				
Issuance of shares	200,000,000	-	-	200,000,000
	200,000,000	-	-	200,000,000
Comprehensive income for the period:				
Profit after taxation	-	-	(5,903,454)	(5,903,454)
Other comprehensive income for the period	-	-	-	-
Total comprehensive loss for the period	-	-	(5,903,454)	(5,903,454)
Balance as at March 31, 2026 (un-audited)	1,130,403,670	-	(302,446,730)	827,956,940

The annexed notes 1 to 26 form an integral part of these condensed interim financial statements.



Chief Executive



Director



Chief Financial Officer



LIVEN PHARMA LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED MARCH 31, 2026

1 STATUS AND NATURE OF BUSINESS

1.1 Liven Pharma Limited (Formerly: Landmark Spinning Industries Limited) (the Company) was registered on October 21, 1991 under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017) as a private limited Company in Pakistan and subsequently converted into public limited Company as on April 30, 1992. The shares of the Company are quoted on Pakistan Stock Exchange Limited (PSX). The principal activity of the Company was trading, manufacturing, and selling of yarn. The Company changed its principle line of business under the scheme of arrangement sanctioned by the Honorable High Court of Sindh, Karachi and the principal line of business has been changed from "Textile Spinning" to "Pharmaceuticals."

The Company changed its registered office under the arrangement sanctioned by the Honorable High Court of Sindh, Karachi from Sindh to Punjab.

The registered office and manufacturing facility of the Company is located at 49-KM, Multan Road, Phool Nagar District Kasur.

1.2 The operations of the Company were suspended on November 29, 2002, to forestall the recurring losses on account of power breakdowns / frequent load shedding and had been in suspension since then. As a result, the Securities and Exchange Commission (SECP) in its order dated March 20, 2019, granted sanction to the Registrar, Company Registration Office (CRO), Karachi, to present winding up petition against the Company before the Court under clause (b) of section 304 of the Companies Act, 2017. The Company filed an appeal against the said order, however, the same was refused by the Commission vide letter No. 5(10) Misc/ABR/19 dated April 22, 2019. The winding-up against the Company has not yet been filed.

In response to the continuous effort by the management to revive the Company, on October 28, 2021, the Company received a proposal from Liven Pharmaceutical (Private) Limited, prompting the Board of Directors to authorize management to explore the feasibility of a potential reverse merger. The Company communicated the same to the PSX along with the requisite documents in accordance with Rule 5.22 of the PSX Rule Book "Reverse Merger Regulations" and subsequently received confirmation from the PSX that the proposed transaction qualified as a reverse merger.

The Board of Directors of the Company in their meeting dated April 13, 2022 duly approved the scheme of merger whereby the Liven Pharmaceuticals (Private) Limited will be merged with and into Landmark Spinning Industries Limited in exchange of issuance ordinary shares of Landmark Spinning Industries Limited against the shares of Liven Pharmaceuticals (Private) Limited.

The petition for the scheme of arrangement (the scheme) was filed on May 17, 2022, with the High Court of Sindh. Additionally, the shareholders of the Company have approved the scheme of merger in the Extra Ordinary General Meeting held on June 27, 2022. The scheme is still pending approval by the Court.

During the previous year, the Scheme of Arrangement dated April 25, 2022, for the amalgamation of the entire business and operations of Liven Pharmaceuticals (Pvt.) Limited ("LPL") into the Company was sanctioned by the Honorable High Court of Sindh, Pakistan, on September 2, 2024. As a result of the Court's approval, all assets, rights, liabilities, and obligations of LPL have been amalgamated, transferred, and vested into the Company. This includes adjustments for the factory land, building, plant, and machinery located at Winder Industrial Estate, Sector C, District Lasbella, Baluchistan, which have been settled against the loan from related parties associated with the Company's current sponsors in accordance with the Scheme of Arrangement. Accordingly, the former shareholders of LPL were issued 87% of the issued shares in the merged entity.

LIVEN PHARMA LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED MARCH 31, 2026

Owing to the implementation of Scheme of Arrangement sanctioned by the Honorable High Court of Sindh, Karachi :

- the name of the Company changed from "Landmark Spinning Industries Limited" to "Liven Pharma Limited."
- the principal line of business of the Company changed from "textile spinning" to "pharmaceuticals."
- the registered office of the Company changed from "Sindh" to "Punjab."
- Authorized share capital of the Company increased to Rs. 1 billion.

Furthermore, as a result of the Court's sanction of the Scheme of Arrangement, the Company will continue its pharmaceutical manufacturing business. The management believes that the SECP's prior winding-up order has now become infructuous, as the underlying issue has been resolved and the Scheme of Arrangement was approved with the SECP's comments considered.

- 1.3 During the period, the Board of Directors of Liven Pharma Limited (the "Company"), in its meeting held on Friday, 12th September, 2025 at 10am at 49Km Multan Road, Lahore, resolved to increase the paid-up share capital of the Company by issue of a further 20,000,000 (Twenty million) shares, having face value of PKR10/- (Pak Rupees Ten) each, as right shares, to be offered to the members of the Company in proportion of approximately 21.496 right shares for every 100 ordinary shares held i.e, approximately 21.496% at a price of PKR 10/- (Pak Rupees Ten) per right shares.

2 BASIS OF PREPARATION

- 2.1 These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, "Interim Financial Reporting", issued by the International Accounting Standard Board (IASB) as notified under the Companies Act 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with requirements of IAS 34, provisions of and directives issued under the Companies Act, 2017 have been followed.

- 2.2 These condensed interim financial statements do not include all the information and disclosures required in an annual audited financial statements, and should be read in conjunction with the Company's annual audited financial statements for the year ended June 30, 2025.

3 MATERIAL ACCOUNTING POLICY INFORMATION

- 3.1 The material accounting policy information and methods of computations adopted for the preparation of these condensed interim financial statements are the same as applied in the preparation of the preceding annual audited published financial statements of the Company for the year ended June 30, 2025.

LIVEN PHARMA LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED MARCH 31, 2026

3.2 The preparation of these condensed interim financial statements in conformity with the approved accounting standards requires the use of certain critical accounting estimates. It also requires the management to exercise its judgment in the process of applying the Company's accounting policies. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

During preparation of these condensed interim financial statements, the significant judgments made by the management in applying the Company's accounting policies and the key sources of estimation and uncertainty were the same as those that applied in the preceding annual audited published financial statements of the Company for the year ended June 30, 2025.

4 NEW STANDARDS, AMENDMENTS TO APPROVED ACCOUNTING STANDARDS AND NEW INTERPRETATIONS

Any new standards, amendments to approved accounting standards and interpretation of IFRSs that became effective during the current accounting period were either considered not relevant to the Company's operations or did not have material effect on the accounting policies of the Company.

5 ACCOUNTING ESTIMATES AND JUDGMENTS

Basis of judgments and estimates made by the management in preparation of these condensed interim financial statements are same as those applied to the preceding annual published financial statements of the Company for the year ended June 30, 2025.

6 FINANCIAL RISK MANAGEMENT

The financial risk management objectives and policies adopted by the Company are consistent with those disclosed in the financial statements of the Company for the year ended June 30, 2025.

LIVEN PHARMA LIMITED
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
 FOR THE NINE MONTHS ENDED MARCH 31, 2026**

	Note	Un-audited March 31, 2026 (Rupees)	Audited June 30, 2025 (Rupees)
7 PROPERTY, PLANT AND EQUIPMENT			
Owned assets		663,405,167	658,835,218
Right-of-use assets		4,117,330	7,677,162
		<u>667,522,497</u>	<u>666,512,380</u>
7.1 The right-of-use assets includes motor vehicles and generators.			
8 INTANGIBLE ASSETS			
ERP system		720,666	940,679
Patents		8,054,643	7,500,000
		<u>8,775,309</u>	<u>8,440,679</u>
9 TRADE DEBTS			
Trade debts		100,765,299	96,617,336
Less: Allowance for expected credit loss		(96,786,688)	(87,214,758)
		<u>3,978,611</u>	<u>9,402,578</u>
10 STOCK IN TRADE			
Stock in trade	10.1	118,360,165	121,787,072
Stores, spares and loose tools		1,559,319	1,537,809
		<u>119,919,484</u>	<u>123,324,881</u>
10.1 Stock-in-trade is stated net of a provision for obsolete and slow-moving inventory amounting to Rs. 19,943,730/- (June 30, 2025: Nil).			
11 PREPAYMENTS, DEPOSITS AND ADVANCES			
Advance to supplier		2,411,299	6,513,199
Other advances and prepayments		724,138	826,528
		<u>3,135,437</u>	<u>7,339,727</u>
12 CASH AND BANK BALANCES			
Cash in hand		2,055,644	7,838,947
Cash at bank		176,741,026	45,449
		<u>178,796,670</u>	<u>7,884,396</u>
13 LEASE LIABILITY			
Present value of minimum lease payments against right of use asset		1,407,634	1,836,591
Less: Current maturity		(654,704)	(588,723)
		<u>752,930</u>	<u>1,247,868</u>
14 LONG TERM FINANCING			
<i>From banking companies - secured</i>			
Long term finance		5,980,340	7,596,321
Less: current portion shown under current liabilities		(2,770,378)	(2,498,256)
Non-current portion		<u>3,209,962</u>	<u>5,098,065</u>
15 TRADE AND OTHER PAYABLES			
Trade creditors		32,691,554	38,698,685
Accrued liabilities	15.1	22,798,783	19,865,385
Advance from customer		-	839,429
Withholding income tax payable		785,822	768,372
Sales tax payable		140,074	44,588
Audit fee payable		167,500	517,500
Provident fund payable		314,519	140,971
Levies payable		365,585	813,373
Workers' welfare fund payable		31,818	31,818
		<u>57,295,655</u>	<u>61,720,121</u>

LIVEN PHARMA LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED MARCH 31, 2026

15.1 This includes Rs. 22,608,907/- (June 30, 2025: 17,758,577/-) payable in respect of directors/chief executive's remuneration.

	Note	Un-audited March 31, 2026 (Rupees)	Audited June 30, 2025 (Rupees)
16 LOAN FROM RELATED PARTIES			
<i>Unsecured - considered good</i>			
Loan from director		14,047,263	14,047,263
		<u>14,047,263</u>	<u>14,047,263</u>
17 CURRENT PORTION OF LONG TERM LIABILITIES			
Current portion of lease liabilities	13	654,704	588,723
Current portion of long term financing	14	2,770,378	2,498,256
		<u>3,425,082</u>	<u>3,086,979</u>

18 CONTINGENCIES AND COMMITMENTS

There has been no significant change in the status of contingencies and commitments as reported in the annual financial statements for the year ended June 30, 2025.

	Note	Nine Months Ended Un-audited March 31, 2026 (Rupees)	Nine Months Ended Un-audited March 31, 2025 (Rupees)
19 OTHER INCOME			
Profit on bank deposits		324,142	-
Discount received from vendors		111,560	-
Gain on disposal of property plant and equipment		9,933,636	85,424,621
Liability written back		-	33,871,269
		<u>10,369,338</u>	<u>119,295,890</u>
20 LEVIES			
Minimum tax u/s 154		76,924	-
Minimum tax u/s 113		1,157,837	-
		<u>1,234,761</u>	<u>-</u>
21 TAXATION			
Current tax		-	22,089,128
Deferred tax		(22,582,414)	(11,387,017)
		<u>(22,582,414)</u>	<u>10,702,111</u>

22 TRANSACTIONS WITH RELATED PARTIES

The related parties comprise of associated companies/undertakings, directors of the Company and key management personnel. Details of transactions with related parties during the period other than those which have been disclosed elsewhere in these financial statements are stated below:

Name	Nature of transactions	Mar 31, 2026 (Rupees)	Mar 31, 2025 (Rupees)
Key management personnel			
Mr. Kashif Hussain	Loan obtained from Chief Executive	408,148	12,164,173
Mr. Kashif Hussain	Loan repaid to Chief Executive	(408,148)	-
Mr. Kashif Hussain	Remuneration of Chief Executive	5,400,000	3,000,000
Ms. Firdous Shakir	Remuneration of Director	5,400,000	-
Associated Companies			
Hassan Ali Rice Export Company	Loan adjusted against disposal of fixed assets	-	(184,087,743)
	Liability written back	-	(33,871,269)
Syndicate Minerals Export	Loan adjusted against disposal of fixed assets	-	(20,548,275)

LIVEN PHARMA LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED MARCH 31, 2026

23 FAIR VALUES OF FINANCIAL ASSETS AND LIABILITIES

The following table shows the carrying amounts and fair values of financial assets and financial liabilities including their levels in the fair value hierarchy for financial instruments measured at fair value. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

Description	Carrying amount				Fair Value			
	Fair value through profit/loss	Fair value through OCI	Amortised Cost	Total	Level 1	Level 2	Level 3	Total
.....Rs.....								
March 31, 2025 (Un-audited)								
Financial assets								
Trade debts	-	-	3,978,611	3,978,611	-	-	-	-
Cash and bank balances	-	-	178,796,670	178,796,670	-	-	-	-
	-	-	182,775,281	182,775,281	-	-	-	-
Financial liabilities								
Lease liabilities	-	-	1,407,634	1,407,634	-	-	-	-
Long term financing	-	-	5,980,340	5,980,340	-	-	-	-
Loan from related parties	-	-	14,047,263	14,047,263	-	-	-	-
Trade and other payables	-	-	57,295,655	57,295,655	-	-	-	-
Running finance	-	-	5,930,439	5,930,439	-	-	-	-
Mark up accrued	-	-	110,700	110,700	-	-	-	-
	-	-	84,772,031	84,772,031	-	-	-	-

Description	Carrying amount				Fair Value			
	Fair value through profit/loss	Fair value through OCI	Amortised Cost	Total	Level 1	Level 2	Level 1	Total
.....Rs.....								
June 30, 2025 (Audited)								
Financial assets								
Trade debts	-	-	9,402,578	9,402,578	-	-	-	-
Cash and bank balances	-	-	7,884,396	7,884,396	-	-	-	-
	-	-	17,286,974	17,286,974	-	-	-	-
Financial liabilities								
Lease liabilities	-	-	1,836,591	1,836,591	-	-	-	-
Long term financing	-	-	7,596,321	7,596,321	-	-	-	-
Loan from related parties	-	-	14,047,263	14,047,263	-	-	-	-
Trade and other payables	-	-	61,720,121	61,720,121	-	-	-	-
Running finance	-	-	11,185,166	11,185,166	-	-	-	-
Mark up accrued	-	-	386,020	386,020	-	-	-	-
	-	-	96,771,482	96,771,482	-	-	-	-

24 CORRESPONDING FIGURES


- In order to comply with the requirements of International Accounting Standard (IAS) 34 "Interim Financial Reporting", the condensed interim statement of financial position and the condensed interim statement of changes in equity have been compared with the balances of the annual audited financial statements of the preceding financial year, whereas the condensed interim statement of profit or loss, condensed interim statement of comprehensive income, and condensed interim statement of cash flows have been compared with the balances of the comparable period of the immediately preceding financial year.

25 AUTHORIZATION OF FINANCIAL STATEMENTS

25.1 These condensed interim financial statements were approved and authorized for issue on 29-04-2026 by the Board of Directors of the Company.

26 GENERAL

- Figures have been rounded off to the nearest Pakistan Rupees (PKR), unless otherwise stated.



Chief Executive



Director



Chief Financial Officer

